Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shenxian Quyu Decoction for exercise tolerance after PCI in stable coronary heart disease
ChiCTR2400093260Phase 4Recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Dec 2024
- Countries
- 1
01
Overview
Phase 4, open-label trial of Shengxian-Quyu Decoction in coronary arteriosclerosis (2 arms), sponsored by China-Japan Friendship Hospital. Primary endpoint: Peak oxygen consumption change rate. Started Dec 2024; status: recruiting.
02
Drugs
Shengxian-Quyu Decoction
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2400093260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093260.